Why Tumour Marker Tests Sold to Healthy People Create False Alarms
A blood test that promises to detect cancer early sounds like exactly the kind of thing a cautious person should do. Increasingly, diagnostic labs across India are bundling tests for CA-125, PSA, CEA, AFP, and CA 19-9 into routine health packages marketed to people who feel perfectly well. The logic seems sound. The results, when they arrive, often do not.
What Tumour Markers Actually Measure
Tumour markers are proteins, hormones, or other substances that certain cancer cells produce in larger quantities than normal cells do. A pathologist measuring CA-125 in blood is measuring how much of that protein is circulating at the time of the draw. That is all the test does. It does not look for a tumour. It does not confirm one is present. It reports a number, and that number sits on a spectrum shared by healthy tissue, benign conditions, and malignant disease alike.
CA-125, for example, is associated with ovarian cancer in clinical oncology. It is also elevated in endometriosis, fibroids, pelvic inflammatory disease, and during menstruation. CEA, often flagged in colorectal cancer monitoring, rises in smokers, people with inflammatory bowel disease, and those with liver conditions. PSA, used in prostate cancer follow-up, increases with age, after cycling, after a digital rectal examination, and with benign prostatic hyperplasia. The number alone tells a clinician almost nothing without context.
Why These Tests Were Not Designed for Screening
The distinction between a diagnostic test and a screening test is not semantic. A diagnostic test is used when a clinician already suspects a condition and needs to confirm or rule it out. A screening test is applied to a population without symptoms to identify those who need further investigation. Tumour markers were developed and validated in the first setting, not the second.
The Indian Council of Medical Research does not recommend tumour marker panels as population-level screening tools for asymptomatic individuals. Neither does the World Health Organization. The reason is a concept called positive predictive value. When a condition is rare in a population, as any specific cancer is, even in a high-risk group, a test with a modest false-positive rate will return far more false alarms than true detections. In a group of a thousand healthy adults, a test that is 95 percent specific will still flag fifty people who do not have the disease. Each of those fifty then enters a cascade: repeat tests, imaging, specialist referrals, sometimes biopsies.
The Real Cost of a False Positive
Anxiety from an elevated tumour marker result is not trivial. Research in clinical psychology has documented that patients who receive a false-positive cancer result can carry measurable psychological distress for months, even after follow-up tests confirm no disease. In India, where oncology specialist access varies sharply between cities and smaller towns, the follow-up cascade can take weeks to resolve and carries its own financial weight.
There is also a physical cost. A biopsy, even when it returns a benign result, carries procedural risks. Imaging with contrast agents carries its own considerations for people with kidney function concerns. None of these downstream risks appear in the marketing language of a wellness package that lists a tumour marker panel alongside a lipid profile and a thyroid screen.
When Tumour Marker Tests Do Have a Role
These tests earn their place in medicine when used the way they were designed to be used. A person already diagnosed with ovarian cancer has CA-125 measured at intervals to track whether treatment is working or whether the disease has returned. A man being monitored after prostate cancer treatment has PSA measured for the same reason. In these contexts, the baseline is established, the trend matters more than any single number, and the result is interpreted by an oncologist with full clinical knowledge of the patient.
A GP or oncologist may also order a specific marker when symptoms point toward a particular cancer, unexplained weight loss, a palpable mass, persistent abdominal distension, as part of a broader workup. That is a clinical decision made in the presence of signs. It is categorically different from a lab offering the same test to a person who walked in for a routine check.
What to Do If You Have Already Had One
If a result has come back elevated and you have no symptoms, the single most useful step is to take the report to a physician, not back to the lab. A doctor can assess what the number means given your age, sex, medication history, and any conditions already on record. In many cases the appropriate response is a repeat test after a short interval, because transient elevations resolve on their own. In some cases further investigation is genuinely warranted. Only a clinician with your full picture can make that call.
Refusing to investigate an elevated result is not the answer either. The point is not that these numbers are meaningless. It is that their meaning depends entirely on who is reading them and what else is known about the person they came from.
The demand for early cancer detection is understandable and the instinct behind it is sound. The problem is that a test designed for one purpose does not become useful for another simply because it is available and affordable. Tumour markers in a healthy adult without symptoms generate far more noise than signal, and navigating that noise has real costs that never appear on the lab invoice.